Skip to main content

Maltodextrin: A Novel Excipient Used in Sugar-Based Orally Disintegrating Tablets and Phase Transition Process

Abstract

The recent challenge in orally disintegrating tablets (ODT) manufacturing encompasses the compromise between instantaneous disintegration, sufficient hardness, and standard processing equipment. The current investigation constitutes one attempt to fulfill this challenge. Maltodextrin, in the present work, was utilized as a novel excipient to prepare ODT of meclizine. Tablets were prepared by both direct compression and wet granulation techniques. The effect of maltodextrin concentrations on ODT characteristics—manifested as hardness and disintegration time—was studied. The effect of conditioning (40°C and 75% relative humidity) as a post-compression treatment on ODT characteristics was also assessed. Furthermore, maltodextrin-pronounced hardening effect was investigated using differential scanning calorimetry (DSC) and X-ray analysis. Results revealed that in both techniques, rapid disintegration (30–40 s) would be achieved on the cost of tablet hardness (about 1 kg). Post-compression conditioning of tablets resulted in an increase in hardness (3 kg), while keeping rapid disintegration (30–40 s) according to guidance of the FDA for ODT. However, direct compression-conditioning technique exhibited drawbacks of long conditioning time and appearance of the so-called patch effect. These problems were, yet, absent in wet granulation-conditioning technique. DSC and X-ray analysis suggested involvement of glass-elastic deformation in maltodextrin hardening effect. High-performance liquid chromatography analysis of meclizine ODT suggested no degradation of the drug by the applied conditions of temperature and humidity. Overall results proposed that maltodextrin is a promising saccharide for production of ODT with accepted hardness-disintegration time compromise, utilizing standard processing equipment and phenomena of phase transition.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Armando YP, Schramm SG, Silva M, Kano EK, Koono EEM, Porta V et al. Bioequivalence assay between orally disintegrating and conventional tablet formulations in healthy volunteers. Int J Pharm. 2009;336:149–53.

    Article  Google Scholar 

  2. Chandrasekhar R, Hassan Z, AlHusban F, Smith AM, Mohammed AR. The role of formulation excipients in the development of lyophilised fast disintegrating tablets. Eur J Pharm Biopharm. 2009;72:119–29.

    Article  CAS  PubMed  Google Scholar 

  3. Kuno Y, Kojima M, Nakagami H, Yonemochi E, Terada K. Effect of the type of lubricant on the characteristics of orally disintegrating tablets manufactured using the phase transition of sugar alcohol. Eur J Pharm Biopharm. 2008;69:986–92.

    Article  CAS  PubMed  Google Scholar 

  4. Xu J, Bovet LL, Zhao K. Taste masking microspheres for orally disintegrating tablets. Int J Pharm. 2008;359:63–9.

    Article  CAS  PubMed  Google Scholar 

  5. Jain RA, Brito L, Straub JA, Tessier T, Bernstein H. Effect of powder processing on performance of fenofibrate formulations. Eur J Pharm Biopharm. 2008;69:727–34.

    Article  CAS  PubMed  Google Scholar 

  6. Fini A, Bergamante V, Ceschel GC, Ronchi C, Fonseca CA. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008;69:335–41.

    Article  CAS  PubMed  Google Scholar 

  7. Breitkreutz J. European perspectives on pediatric formulations. Clin Therap. 2008;30:2146–54.

    Article  Google Scholar 

  8. Factor SA. Current status of symptomatic medical therapy in Parkinson’s disease. Neurotherapeutics. 2008;5:164–80.

    Article  CAS  PubMed  Google Scholar 

  9. Lader M. Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacology. 2007;17:743–55.

    Article  CAS  Google Scholar 

  10. Panigrahi D, Baghel S, Mishra B. Mouth dissolving tablets: an overview of preparation techniques, evaluation and patented technologies. J Pharm Research. 2005;4:33–8.

    Google Scholar 

  11. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharm Tech. 2003;27:92–100.

    CAS  Google Scholar 

  12. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Contr Release. 2005;105:16–22.

    Article  CAS  Google Scholar 

  13. Mizumoto T, Yoshinori M, Yamamoto T, Yonemochi E, Katsuhide T. Formulation of novel fast-disintegrating tablets. Int J Pharm. 2005;306:83–90.

    Article  CAS  PubMed  Google Scholar 

  14. Sugimoto M, Maejima T, Narisawa S, Matsubara K, Yoshino H. Factors affecting the characteristics of rapidly disintegrating tablets in the mouth prepared by the crystalline transition of amorphous sucrose. Int J Pharm. 2005;296:64–72.

    Article  CAS  PubMed  Google Scholar 

  15. Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilization using hydrochlorothiazide as a model drug. Int J Pharm. 1997;152:215–25.

    Article  CAS  Google Scholar 

  16. Moffat AC, Osselton MD, Widdop B. Clarke's analysis of drugs and poisons. 3rd ed. London: Pharmaceutical; 2004.

    Google Scholar 

  17. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of compressed tablets rapidly disintegrating in oral cavity. Chem Pharm Bull. 1996;44:2121–7.

    CAS  PubMed  Google Scholar 

  18. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Orally Disintegrating Tablets. 2007 http://www.fda.gov/cder/guidance/index.htm. Accessed 16 June 2007.

  19. Papadimitriou E, Efentakis M, Choulis NH. Evaluation of maltodextrins as excipients for direct compression tablets and their influence on the rate of dissolution. Int J Pharm. 1992;86:131–6.

    Article  CAS  Google Scholar 

  20. Labuza T. Literature review on: water activity and glass transition. University of Minnesota, Department of food science and nutrition. 2007. http://www.faculty.che.umn.edu. Accessed 15 April 2007.

  21. Sperling LH. Introduction to physical polymer science. New York: Wiley; 1986. p. 224–95.

    Google Scholar 

  22. Ferry JD. Viscoelastic properties of polymers. New York: Wiley; 1980. p. 264–320.

    Google Scholar 

  23. Roozen MJ, Hemminga MA, Walstra P. Molecular motion in glassy water malto- oligosaccharide (maltodexrtin) mixtures as studied by conventional and saturation-transfer spin-probe spectroscopy. Carbohydr Res. 1991;215:229–37.

    Article  CAS  Google Scholar 

  24. Yunxia B, Yorinobu Y, Hisakazu S. Rapidly disintegrating tablets prepared by the wet compression method: mechanism and optimization. J Pharm Sci. 1999;88:1004–10.

    Article  Google Scholar 

  25. Li LC, Peck GE. The effect of moisture content on the compression properties of maltodextrins. J Pharm Pharmacol. 1990;42:272–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yosra Shaaban R. Elnaggar.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Elnaggar, Y.S.R., El-Massik, M.A., Abdallah, O.Y. et al. Maltodextrin: A Novel Excipient Used in Sugar-Based Orally Disintegrating Tablets and Phase Transition Process. AAPS PharmSciTech 11, 645–651 (2010). https://doi.org/10.1208/s12249-010-9423-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-010-9423-y

Key words

  • disintegration time
  • maltodextrin
  • meclizine
  • orally disintegrating tablets
  • phase transition